Myriad Genetics Inc (MYGN)

Financial leverage ratio

		Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Total assets	US$ in thousands	1,085,100	1,110,500	1,146,500	1,149,100	1,187,200	1,169,300	1,198,700	1,212,000	1,210,200	1,255,400	1,320,700	1,335,900	1,360,300	1,336,900	1,444,500	1,404,600	1,446,700	1,578,300	1,591,200	1,562,700
Total stockholders’ equity	US$ in thousands	740,500	760,000	783,200	683,400	735,200	835,200	885,800	916,600	947,400	950,100	967,800	968,600	902,500	875,200	909,300	918,200	967,200	1,077,200	1,074,500	1,088,900
Financial leverage ratio		1.47	1.46	1.46	1.68	1.61	1.40	1.35	1.32	1.28	1.32	1.36	1.38	1.51	1.53	1.59	1.53	1.50	1.47	1.48	1.44

June 30, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,085,100K ÷ $740,500K
= 1.47

The financial leverage ratio of Myriad Genetics Inc has shown some fluctuations over the past few quarters, ranging from 1.28 to 1.68. The trend indicates that the company has been gradually increasing its leverage over time, with a peak in September 2023 at 1.68 before slightly decreasing in subsequent quarters. A financial leverage ratio above 1 suggests that the company relies more on debt to finance its operations compared to equity.

While a higher leverage ratio can amplify returns for shareholders in good times, it also increases financial risk, especially during economic downturns or in periods of high interest rates. It is essential for investors and stakeholders to monitor Myriad Genetics Inc's leverage ratio closely to assess its ability to meet its debt obligations and manage financial stability effectively.